Junten Bio Co., Ltd.

Koichiro Uchida

Ko Okumura

Kazuyoshi Takeda

Masayuki Kawakami

Ryu Maeda

The present disclosure provides a pharmaceutical composition for antigen-specific immune tolerance or immune present suppression. The disclosure provides pharmaceutical composition comprising a CD-positive anergy T cell and a CD-positive anergy T cell. In some embodiments, the anergy T cell is induced by an antibody capable of inhibiting the interaction between CDand/or CDand CD. In a specific embodiment, the pharmaceutical composition May additionally comprise a regulatory T cell (e.g., a FOXP-positive CD-positive CD-positive T cell).

Antibody capable of inducing immune tolerance produced using cell mixture having complexed state, and induced lymphocyte or cell therapeutic agent and cell therapy method each using induced lymphocyte

The present disclosure provides a novel technique relating to immunological tolerance. More specifically, the present inventor found for the first time that, in a technique for inducing immunological tolerance by administering an organ transplantation patient (a recipient) a cell preparation containing cells in which anergy is induced by an inhibitor inhibiting the interaction between CD80/CD86 and CD28, the immunological tolerance continues even after the disappearance of the cells derived from the cell preparation from the recipient (infectious immunological tolerance). Further, the present inventor proved that such a cell preparation can elicit immunological tolerance against immunological rejection caused by allergy, iPS cells, etc. or cells, tissues or organs derived therefrom.

Method for eliciting infectious immunological tolerance

The present disclosure provides an antibody for inducing immune tolerance, an induced lymphocyte, and a cell therapy agent therapeutic method using the induced lymphocyte. Specifically, the present disclosure provides an antibody that inhibits the interaction between CD80 and/or CD86 expressed on the surface of a certain cell and CD28 expressed on the surface of another cell, and substantially does not induce immune activation-induced cytokines. In a specific embodiment, the Fc portion of the antibody substantially does not produce the immune activation-induced cytokines.

Growing community of inventors

Tokyo, Japan

Koichiro Uchida